

Publikationsverzeichnis

Erst- / Letztautorenschaften

Originalarbeiten

1. **Kast K**, Wimberger P, Arnold N. Changes in classification of genetic variants in BRCA1 and BRCA2. Arch Gynecol Obstet. 2018 Feb;297(2):279-280.
2. Sadowski CE, Kohlstedt D, Meisel C, Keller K, Becker K, Mackenroth L, Schröck E, Wimberger P, **Kast K**. BRCA1/2 missense mutations and the value of in-silico analyses. Eur J Med Genet. 2017 Nov; 60(11):572-577. IF: 2.137
3. **Kast K**, Schoffer O, Link T, Forberger A, Petzold A, Niedostatek A, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P. Trastuzumab and survival of patients with metastatic breast cancer. Arch Gynecol Obstet. 2017 Aug;296(2):303-312. IF: 2.090
3. Meisel C, Sadowski CE, Kohlstedt D, Keller K, Dunkel F, Grübling N, Becker K, Mackenroth L, Arnold N, Schröck E, Wimberger P, **Kast K**. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. Arch Gynecol Obstet. 2017 May;295(5):1227-1238. IF: 2.090
4. **Kast K**, Dobberschütz C, Sadowski CE, Pistorius S, Wimberger P. Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer. Arch Gynecol Obstet. 2016 Nov;294(6):1299-1303. IF: 2.090
5. **Kast K**, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016 Feb 29. pii: jmedgenet-2015-103672. IF: 5,703
6. **Kast K**, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015 Apr;150(3):621-9. doi:10.1007/s10549-015-3341-3. Epub 2015 Mar 18. Breast Cancer Res Treat. 2015 Apr;150(3):621-9. IF: 4.085
7. **Kast K**, Schmutzler RK, Rhiem K, Kiechle M, Fischer C, Niederacher D, Arnold N, Grimm T, Speiser D, Schlegelberger B, Varga D, Horvath J, Beer M, Briest S, Meindl A, Engel C. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J Cancer. 2014; 135(10):2351-2361. IF:5.085

Übersichtsarbeiten

1. **Kast K**, Grill S, Kiechle M, Sport und Prävention, gynäkologische praxis, Zeitschrift für Frauenheilkunde und Geburtshilfe, eingereicht 10.08.2017 IF –
2. **Kast K**, Arnold N. Personalisierte Medizin bei soliden Tumoren. Medizinische Genetik December 2016, Volume 28, Issue 4, pp 443–451 IF: 0,10
2. **Kast K**, Ditsch N, Kiechle M, LIFESTYLE und erblicher Brustkrebs. Welche nicht-genetischen Faktoren beeinflussen das Erkrankungsrisiko? Medizinische Genetik 2015 · 27:237–243 IF: 0,10
3. **Kast K**, Rhiem K. Familial breast cancer - targeted therapy in secondary and tertiary prevention. Breast Care (Basel). 2015 Feb;10(1):27-31. IF: 0,627
4. **Kast K**, Fischer C. BRCA1 und BRCA2 – genetische und nichtgenetische Einflussfaktoren. Der Gynäkologe 2014, 47:759-768. IF: 0.06
5. **Kast K**, Arnold N. Gendiagnostik bei familiären Tumoren. Gynäkologe 2012 45:28–34 IF:0,07
6. **Kast K**, Meindl A, Schmutzler RK. Familiärer Brustkrebs. Was gibt es Neues? Best Practice Onkologie, 2011 6(1):4-10 IF -
7. **Kast K**, Schmutzler RK. Prävention und Früherkennung bei Frauen mit familiärer Krebsbelastung. Empfehlungen des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs. Gynäkologische Praxis Zeitschrift für Frauenheilkunde und Geburtshilfe 2010 IF -
8. **Kast K**, Distler W, Schmutzler RK. Aktuelle Empfehlungen zur Prävention und Therapie des familiären Mammakarzinoms, Geburtsh Frauenheilk 2010; 70: 1-6 IF -
9. **Kast K**, Distler W. ErbB2 (HER2)-positives Mammakarzinom. Resistenzmechanismen Gynäkologe 2010 · 43:574–578. IF:0,09
10. **Kast K**, Distler W, Schmutzler RK. Risiko für Brust- und Eierstockkrebs Bedeutung, Beratung, genetische Testung und klinische Empfehlungen zur Prävention. Der Gynäkologe 2009, November IF:0.12
11. **Kast K**, Distler W, Schmutzler RK, Mamma- und Ovarialkarzinome bei BRCA1- oder BRCA2-Mutationsträgerinnen. Neue Strategien einer zielgerichteten Therapie. Gynäkologe 2009; 42:189-193. IF:0.12
12. **Kast K**, Tinschert S, Viehweg P, Distler W, Schröck E, Laniado M. Klinisches Management des familiären Mammakarzinoms. Eine Versorgungsstudie der Krankenkassen. Ärzteblatt Sachsen 2006; 2: 73-76 IF -
13. **Kast K**, Müller S, Distler W. Tumorrisikosprechstunde für hereditäres Mamma- und Ovarialkazinom. Ärzteblatt Sachsen 2002; 4: 154-159 IF -

Fallberichte

1. **Kast K**, Krause M, Schuler M, Thamm B, Bier A, Distler W, Krüger S. Late onset Li-Fraumeni syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. *BMC Cancer* 6;12(1):217 IF:3.36
2. **Kast K**, Neuhann TM, Görgens H, Becker K, Keller K, Klink B, Aust D, Distler W, Schröck E, Schackert HK. Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. *Familial Cancer. BMC Cancer.* 2012 Nov 20;12(1):531. IF:3.36
3. **Kast K**, Wagner A, Klengel J, Distler W. Schwangerschaft bei beidseitigem Borderline-Tumor des Ovars. *Der Gynäkologe* 2005; 38:1038-1041

Co-Autorenschaften

Originalarbeiten (<40 Autoren)

1. Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. *BMC Cancer.* 2018 Mar 7;18(1):265.
2. Harter P, Hauke J, Heitz F, Reuss A, Kommos S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberer M, Brucker S, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R. Prevalence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO TR-1). *PLoS One.* 2017 Oct 20;12(10):e0186043. IF: 3.54
3. Dittrich A, Schubert B, Kramer M, Lenz F, Kast K, Schuler U, Schuler MK. Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction. *Support Care Cancer.* 2017 Apr 22. doi: 10.1007/s00520-017-3700-1, PMID: 28434096 IF: 2.535
4. Hackmann K, Kuhlee F, Betscheva-Krajcir E, Kahlert AK, Mackenroth L, Klink B, Di Donato N, Tzschach A, Kast K, Wimberger P, Schrock E, Rump A. Ready to clone: CNV detection and breakpoint fine-mapping in breast and ovarian cancer susceptibility genes by high-resolution array CGH. *Breast Cancer Res Treat.* 2016 Oct;159(3):585-90. IF:4.085
5. Rump A, Benet-Pages A, Schubert S, Kuhlmann JD, Janavičius R, Macháčková E, Foretová L, Kleibl Z, Lhota F, Zemankova P, Betscheva-Krajcir E, Mackenroth L, Hackmann K, Lehmann J, Nissen A, DiDonato N, Opitz R, Thiele H, Kast K, Wimberger P, Holinski-Feder E, Emmert S, Schröck E, Klink B. Identification and Functional Testing

- of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer. *PLoS Genet.* 2016 Aug 9;12(8):e1006248. IF:7.17
6. Wolf C, Rapp A, Berndt N, Staroske W, Schuster M, Dobrick-Mattheuer M, Kretschmer S, König N, Kurth T, Wieczorek D, Kast K, Cardoso MC, Günther C, Lee-Kirsch MA. RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA. *Nat Commun.* 2016 May 27;7:11752. IF: 11.05
 7. Schroeder C, Faust U, Sturm M, Hackmann K, Grundmann K, Harmuth F, Bosse K, Kehrer M, Benkert T, Klink B, Mackenroth L, Betscheva-Krajcir E, Wimberger P, Kast K, Heilig M, Nguyen HP, Riess O, Schröck E, Bauer P, Rump A. HBOC multi-gene panel testing: comparison of two sequencing centers. *Breast Cancer Res Treat.* 2015 Jul;152(1):129-36. IF: 3.94
 8. Wobus M, List C, Dittrich T, et al. Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. *Int J Cancer.* 2015 Jan 1;136(1):44-54. IF: 5.085
 9. Rhiem K, Engel C, Graeser M, Janni W, Kiechle M, Ditsch N, Mundhenke C, Kreienberg R, Tio J, Golatta M, Honig A, Gadzicki D, Speiser D, Kast K, Briest S, Meindl A, Schmutzler R. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. *Breast Cancer Res.* 2012 Dec 7;14(6):R156 IF: 5.490
 10. Spurdle AB, Whaley PJ, Thompson B, Spurdle AB, Whaley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C; kConFab, Van Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM; Dutch Belgium UV Consortium, Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A; German Consortium of Hereditary Breast and Ovarian Cancer, Caputo S, Sinilnikova OM, Lidereau R; French COVAR group collaborators, Couch FJ, Guidugli L, Hansen Tv, Thomassen M, Eccles DM, Tucker K, Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg Å, Vreeswijk MP, Goldgar DE; ENIGMA Consortium BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *J Med Genet.* 2012 Aug;49(8):525-32. IF: 5.703
 11. Dick MG, Versmold B, Engel C, Meindl A, Arnold N, Varon-Mateeva R, Sutter C, Niederacher D, Deissler H, Preisler-Adams S, Kast K, Schäfer D, Gadzicki D, Heinritz W, Wappenschmidt B, Schmutzler RK. Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers. *Int J Cancer.* 2011 Apr 11. IF: 1.65
 12. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Müller-Myshok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nature Genetics* 2010; 42(5): 410-416. IF: 20.02
 13. Hemminki K, Müller-Myshok B, Lichtner P, Engel C, Försti A, Sutter C, Wappenschmidt B, Hellebrandt H, Illig T, Arnold N, Niederacher D, Dworniczak B, Deissler H, Kast K, Gadzicki D, Meitinger T, Wichmann HE, Kiechle M, Bartram CR, Schmutzler RK, Meindl A. Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer

patients. *Int J Cancer*. 2010 Jun 15;126(12):2858-62.

IF:0.92

14. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *J Clin Oncol* 2009; 27:5887-5892. IF: 12.10
15. Wappenschmidt B, Becker AA, Hauke J, Weber U, Engert S, Köhler J, Kast K, Arnold N, Rhiem K, Hahnen E, Meindl A, Schmutzler RK. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. *PLoS One*. 2012;7(12):e50800. IF:4.82
16. Engert S, Wappenschmidt B, Betz B, Kast K, Kutsche M, Hellebrand H, Goecke TO, Kiechle M, Niederacher D, Schmutzler RK, Meindl A. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: Novel deletions, frequent involvement of exon 17, and occurrence in single early onset-cases. *Human Mutation* 2008; 29(7), 948-950. IF: 6.04

Co-Autorenschaften (> 40 Autoren)

1. Schrijver LH, Olsson H, Phillips KA, Terry MB, Goldgar DE, Kast K, ..., Antonis C, Antoniou, Matti A, Rookus; on behalf of EMBRACE, GENEPSO, BCFR, HEBON, kConFab, and IBCCS. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study, *JNCI Cancer Spectrum*, 2018, Vol. 00, No. 0 [Epub ahead of print]
2. Mikropoulos C, Selkirk CGH, Saya S, Bancroft E,.....Kast K, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *Br J Cancer*. 2018 Jan 4. doi: 10.1038/bjc.2017.429.
3. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J ... Kast K, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet*. 2017 Oct 23. doi: 10.1038/ng.3785. IF: 13.45
4. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu NEngel C, **Kast K**, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA*. 2017 Jun 20;317(23):2402-2416. IF:4.01
5. Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE...**Kast K**, Arnold N, Ditsch N,... Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *J Clin Oncol*. 2017 Jul 10;35(20):2240-2250. IF:18.428
6. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K.... Karnezis A, **Kast K**; KConFab Investigators,.....Sellers TA, Gayther SA, Antoniou AC, Pharoah PDP.

- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet.* 2017 May;49(5):680-691 IF:31.616
7. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J,... **Kast K**, Pharoah PD, Chenevix-Trench G, Antoniou AC. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS One.* 2016 Jul 27;11(7):e0158801. IF:3.54
 8. Silvestri V, Barrowdale D, Mulligan AM **Kast K**, Arnold N, ...Chenevix-Trench G, Antoniou AC, Ottini L. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res.* 2016 Feb 9;18(1):15. IF:0.84
 9. Blein S, Bardel C, Danjean V, ...Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, **Kast K**, Rhiem K, Ditsch N, Arnold N.... Sinilnikova OM, Cox DG. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res.* 2015 Apr 25;17:61. IF:0.84
 10. Rebbeck TR, Mitra N, Wan F, Gadzicki D, Steinemann D, **Kast K**, Beer M, Varon-Mateeva RHulick PJ, Andrulis I. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA.* 2015 Apr 7;313(13):1347-61. Erratum in: *JAMA.* 2015 Aug 11;314(6):628. IF:5.21
 11. Blanco I, Kuchenbaecker K, Cuadras D, Preisler-Adams S, **Kast K**, Varon-Mateeva R, Couch FJ, Antoniou AC, Pujana MA. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS One.* 2015 Apr 1;10(4):e0120020. IF:3.54
 12. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, et al. Collaborators: Green AC, Parsons PG,..... **Kast K**, Rhiem K,.... Pharoah PP, Antoniou AC, Chenevix-Trench G;. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet.* 2015 Feb;47(2):164-71. IF:13.45
 13. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, ... **Kast K**, Rhiem K, KConFab Investigators, Antoniou AC, Friedman E. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 2015 Jan;24(1):308-16. IF: 3.94
 14. Osorio A, Milne RL, Kuchenbaecker K, ... **Kast K**, Couch FJ, Chenevix-Trench G, Antoniou AC, Benitez J. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genet.* 2014 Apr;10(4):e1004256. IF: 8.35
 15. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK ... **Kast K**....., Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res.* 2014 Dec 31;16(6):3416. IF: 0.48
 16. Spurdle AB, Couch FJ, Parsons MT, ...Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, **Kast K**,.... EMBRACE Group.; GENICA Network.; HEBON Group.;

- kConFab Investigators. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Res.* 2014 Dec 23;16(6):3419.
IF: 0.48
17. Couch F Wang X, McGuffog L, ... **Kast K**, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. *PLOS Genetics*, March 2013;9(3):e1003212.
IF: 8.35
 18. Ding YC, McGuffog L, Healey S, ... **Kast K**, ... Antoniou AC, Neuhausen SL; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)..A non-synonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 2012; 21(8):1362-1370. Epub 2012 Jun 22. Erratum in: *Cancer Epidemiol Biomarkers Prev.* 2012 Dec;21(12):2278.
IF:5.23
 19. Couch FJ, Gaudet MM, Antoniou AC, ... **Kast K**,Chenevix-Trench G; kConFab investigators, Offit K, Simard J; Consortium of Investigators of Modifiers of BRCA1/2. Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *Cancer Epidemiol Biomarkers Prev.* 2012 Apr;21(4):645-57.
IF: 5.23
 20. Antoniou AC, Kuchenbaecker KB, Soucy P, ... **Kast K**, CIMBA, SWE-BRCA.; HEBON.; EMBRACE.; GEMO Collaborators Study.; kConFab Investigators.. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Res.* 2012 Feb 20;14(1):R3
IF: 0.16
 21. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Silnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, ... **Kast K**... Easton DF, Couch FJ, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Hum Mutat.* 2012 Apr;33(4):690-702.
IF:5.69
 22. Mavaddat N, Barrowdale D, Andrulis IL, ...**Kast K** ... Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev.* 2012 Jan;21(1):134-47.
IF:5.23
 23. Mulligan AM, Couch FJ, Barrowdale D ...**Kast K**, ... HEBON.; kConFab Investigators.; Ontario Cancer Genetics Network.; SWE-BRCA.; CIMBA. Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res.* 2011 Nov 2;13(6):R110.
IF: 0.10
 24. Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L ...**Kast K**, ...

- Antoniou AC, Couch FJ, Offit K, Gold B. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Hum Genet.* 2011 Nov;130(5):685-99. IF:2.72
25. Antoniou AC, Kartsonaki C, Sinilnikova, ...**Kast K**, OM Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; CIMBA. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet.* 2011 Aug 15;20(16):3304-21. IF: 5.15
26. Ramus SJ, Kartsonaki C, Gayther SA, ...**Kast K**, ... Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst.* 2011 Jan 19;103(2):105-16. IF:3.40
27. Antoniou AC, Beesley J, McGuffog L, ... **Kast K**, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X; kConFab., Platte R, Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Res.* 2010 Dec 1;70(23):9742-54. IF: 0.23
28. Engel C, Vermold B, Wappenschmidt B, **Kast K**,... Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 2010 Nov;19(11):2859-68. IF:3.14
29. Rebbeck T, Antoniou A, ... **Kast K**, Schaefer D, Froster UG, Chenevix-Trench G, Easton DF. No association of TGFB1 L10P genotypes and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers: a multi-center cohort study. *Breast Cancer Res Treat.* 2009; 115(1):185-192. IF:3.32

Collaborator

1. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. *Lancet.* 2016 Feb 27;387(10021):866-73.
2. von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B; GBG/AGO-B study groups. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). *Ann Oncol.* 2014 Dec;25(12):2363-72.
3. Cuzick J, Sestak I, Forbes JF, et al.; IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet.* 2014 Mar 2;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Erratum in: *Lancet.* 2014 Mar 22;383(9922):1040. (Appendix)

4. Untch M, Loibl S, Bischoff J, et al. (Supplement: Collaborators) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *The Lancet Oncol.* 2012 13(2):135–144
5. Spurdle AB, Whaley PJ, Thompson B, Feng B, Healey S, Brown MA, ... Meindl A; German Consortium of Hereditary Breast and Ovarian Cancer, Caputo S,.... Goldgar DE; ENIGMA Consortium. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *J Med Genet.* 2012 Aug;49(8):525-32.

Übersichtsarbeiten

1. Waha A, Versmold B, Kast K, Kiechle M, Ditsch N, Meindl A, ... Schmutzler RK, Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse Geburtshilfe und Frauenheilkunde; Ausgabe 07, 2017, *Geburtshilfe Frauenheilkd* 2017; 77(07): 733-739
IF: -
2. Meindl A, Rhiem K, Engel C, Ditsch N, Kast K, Hahnen E, Schmutzler RK, Klinik und Genetik des familiären Brust- und Eierstockkrebses, *medgen* 2013, 25:259–277 DOI 10.1007/s11825-013-0390-z Online publiziert: 4. Juli 2013
IF: 0.29
3. Meindl A, Ditsch N, **Kast K**, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. *Dtsch Arztebl Int.* 2011 May;108(19):323-30
IF: 0.40
4. Distler W, **Kast K**, Canzler U, Adipositas und Karzinogenese des Mammakarzinoms. *Gynäkologe* 2010; 43:552-558
IF:0.11
5. Goeckenjan M, **Kast K**, Distler W, Wimberger P. Fertilitätsreduktion durch Chemotherapie in der gynäkologischen Onkologie, *Der Gynäkologe*, 09/2013
IF:0.11
6. Schmutzler R, Schwarz-Boeger U, Bastert G, Bender, Beckmann, Caffier, Crohns, Deininger J, Dietl, Ditsch, Distler, Estevez-Schwarz, Hahn W, Herröder, Hübbel, Hüttner, Jackisch, Kandl, Kast K, Kuschel, Luck, Von Minckwitz, Nestle-Krämling, Prieshof B, Rensing, Rhiem, Schäffer, Straub, Untch, Volm T, Kiechle M. Indications for BRCA1 and BRCA2 mutation testing in hereditary breast and ovarian cancer families. *J Clin Oncol.* 2004 Jul 15;22(14_suppl):9720.
IF: 1.63
7. Schmutzler R, Schlegelberger B, et. al. Beratung, Genetische Testung und Prävention von Frauen mit einer familiären Belastung für das Mamma- und Ovariakarzinom. *Zentralbl Gynakol* 2003; 125: 494-506
IF: 0.22

Buchbeitrag

1. **Kast K**, Kontrazeption, *Blauer Ratgeber*, DKH 2014

2. **Kast K**, Verhütung (Stand Pille), Blauer Ratgeber, DKH 2014
3. **Kast K**, Hormone, Hormone, Hormone? - Von Antibaby-Pille bis Demenz. MammaMIA spezial, Komme ich aus einer Krebsfamilie? Informationen für Männer und Frauen zum Familiären Brust- und Eierstockkrebs, Kapitel 8, 2. Aktualisierte Auflage 2013
4. **Kast K**, Die Behandlung familiärer Tumoren. MammaMIA spezial, Komme ich aus einer Krebsfamilie? Informationen für Männer und Frauen zum Familiären Brust- und Eierstockkrebs, Kapitel 8, 2. Aktualisierte Auflage 2013
5. **Kast K**, Onkologische Erkrankungen – Gynäkologische Tumoren, Palliativmedizin – 1000 Fragen, Sabatowski, Maier, Ostgathe, Rolke, 1. Auflage, Kapitel 9.0, MN 278520101, Thieme Verlag, 2013
6. **Kast K**, Rhiem, Schmutzler, et al. Genetische Beratung bei gynäkologischen Erkrankungen, Die Gynäkologie, Kaufmann, Costa Scharl, Springer Verlag, 3. Auflage, Seite 757-766, ISBN: 978-3-642-20922-2, 2013
7. Schmutzler R, **Kast K**. Familiäres Mammakarzinom –Beratung und Betreuung betroffener Familien. Mammakarzinom Interdisziplinär. Kreienberg, Möbus, Jonat, Kühn. Springer Verlag, 4. Auflage, 2010
8. **Kast K**, Die Behandlung familiärer Tumoren. MammaMIA spezial, Komme ich aus einer Krebsfamilie? Informationen für Männer und Frauen zum Familiären Brust- und Eierstockkrebs, Kapitel 7, Ratgeber 01/2009